48 withdrawn. 48 Phase 2, 11 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Withdrawn 48 |
| Phase 1 | 11 | Withdrawn 11 |
| Phase 3 | 7 | Withdrawn 7 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation MET-2, Placebo - Gram-negative Bacteremia, Microbial Colonization | Phase 2 | Withdrawn | University Health Network, Toronto | 2026-07-01 | 2026-03-12 | |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis Gentamicin, Placebo - Urinary Tract Infections, Sepsis | Phase 2 | Withdrawn | Yale University | 2024-10-01 | 2025-01-16 | |
| Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure. Human albumin, Saline solution - Septic Shock | Phase 2 | Withdrawn | Albimmune SL | 2024-02-01 | 2024-07-31 | |
| Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation XPro1595, Placebo - Mild Cognitive Impairment (MCI), Alzheimer Disease | Phase 2 | Withdrawn | Inmune Bio, Inc. | 2023-06-01 | 2023-09-28 | |
| Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE) High-dose/short-duration Fisetin, Low-dose/sustained-duration Fisetin, Oral placebo capsule - Osteoarthritis, Knee | Phase 1 / Phase 2 | Withdrawn | Austin V Stone | 2023-06-01 | 2022-07-29 | |
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation Palmitoylethanolamide, Placebo - Tibial Fractures, Fibula Fracture | Phase 2 | Withdrawn | University of California, Irvine | 2023-05-01 | 2023-05-09 | |
| CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 DeltaRex-G - COVID-19, Cytokine Storm | Phase 1 / Phase 2 | Withdrawn | Aveni Foundation | 2022-12-12 | 2025-02-24 | |
| Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial VB-201, Placebo - Inflammation, HIV Infection | Phase 1 / Phase 2 | Withdrawn | Priscilla Hsue, MD | 2022-07-01 | 2022-09-15 | |
| The Effect of Inflammation in Heart Failure Dapagliflozin, MRI scan, CMR imaging - Myocardial Dysfunction, Heart Failure | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2022-06-23 | 2022-06-27 | |
| Gram Type Infection-Specific Sepsis Identification Using Machine Learning InSight - Sepsis, Severe Sepsis | Phase 2 | Withdrawn | Dascena | 2022-05-01 | 2021-09-23 | |
| Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection Tazemetostat - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 2 | Withdrawn | Loma Linda University | 2022-01-01 | 2021-11-22 | |
| Anakinra, COVID-19, Cytokine Storm Anakinra, 0.9% Saline - Covid19, Cytokine Storm | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2021-12-01 | 2022-01-25 | |
| Safety and Efficacy of Ruxolitinib for COVID-19 Ruxolitinib - COVID-19 | Phase 2 / Phase 3 | Withdrawn | University of Colorado, Denver | 2021-07-01 | 2021-03-08 | |
| Safety and Efficacy of Baricitinib for COVID-19 Baricitinib - COVID-19 | Phase 2 / Phase 3 | Withdrawn | University of Colorado, Denver | 2021-03-01 | 2021-03-08 | |
| Red Cell Rejuvenation for the Attenuation of Transfusion Associated Organ Injury in Cardiac Surgery rejuvesol Solution, Standard Care - Organ Failure, Multiple, Inflammation | Phase 2 | Withdrawn | University of Leicester | 2020-12-01 | 2021-04-29 | |
| Subpopulation-Specific Sepsis Identification Using Machine Learning CustomSight - Sepsis, Severe Sepsis | Phase 2 | Withdrawn | Dascena | 2020-12-01 | 2021-09-23 | |
| RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM Doxycycline, Placebo - Cytokine Storm, SARS-CoV-2 | Phase 2 | Withdrawn | Temple University | 2020-06-22 | 2021-04-19 |
Showing 20 of 48. Sign in to see all of them.
Sepsis (14) · Cytokine Release Syndrome (9) · Shock, Septic (8) · Bacteremia (4) · COVID-19 (4) · Disease (3) · Respiratory Distress Syndrome (3) · Atherosclerosis (2) · Cellulitis (2) · Cognitive Dysfunction (2) · Pain (2) · Schizophrenia (2) · Staphylococcal Infections (2) · Acquired Immunodeficiency Syndrome (1)
Pathologic Processes (48) · Pathological Conditions, Signs and Symptoms (48) · Systemic Inflammatory Response Syndrome (28) · Infections (27) · Shock (18) · Bacterial Infections and Mycoses (7) · Immune System Diseases (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Virus Diseases (7) · Cardiovascular Diseases (6) · Pneumonia (6) · RNA Virus Infections (6) · Respiratory Tract Infections (6)
Saline Solution (3) · Butyric Acid (2) · Interleukin 1 Receptor Antagonist Protein (2) · Magnetic Resonance Imaging (2) · lactoferrin (1-11), human (2) · tocilizumab (2) · 1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine (1) · ALT-803 (1) · Adalimumab (1) · Anti-Bacterial Agents (1) · Azithromycin (1) · Bevacizumab (1) · Biopsy (1) · Cell Count (1) · Chlorhexidine (1)
Dascena (3) · University of Colorado, Denver (3) · AM-Pharma (2) · Weill Medical College of Cornell University (2) · Albimmune SL (1) · All India Institute of Medical Sciences (1) · Austin V Stone (1) · Aveni Foundation (1) · Basilea Pharmaceutica (1) · Children's Hospital of Philadelphia (1) · Gil Joon Suh (1) · ImmunityBio, Inc. (1) · Inmune Bio, Inc. (1) · Jack Khouri, MD (1) · Kevin McNerney (1)
United States (17) · Netherlands (3) · Canada (2) · China (2) · United Kingdom (2) · India (1) · Norway (1) · Singapore (1) · South Korea (1)
Ritankar Das, MSc (3) · Joaquin Espinosa, PhD (2) · Professor P.E. Verweij, MD, PhD (2) · Ariana Nelson, MD (1) · Arthur M Feldman, MD, PhD (1) · Austin Stone, MD, PhD (1) · Bryan Coburn, MD, PhD (1) · Chunbo Li, M.D. (1) · Ciprian P Gheorghe, MD, PhD (1) · David Lye, MBBS, FRACP (1) · David Teachey, MD (1) · Diego de Villalobos, MD (1) · Douglas Kwon, MD, PhD (1) · Gavin J Murphy, Prof (1)
K01AA026005 (1), K12TR005104 (1), P30AG028740 (1)